Associated Papers
Longitudinal proteomic profiling of cerebrospinal fluid in untreated multiple sclerosis defines evolving disease biology.
Kosa P et al.
Nature Communications, 2025
41339376 (PubMed )
Supplement: 41467_2025_65154_MOESM4_ESM.xlsx › Supplementary_data_2
Efficient candidate drug target discovery through proteogenomics in a Scottish cohort.
Kuliesius J et al.
Communications Biology, 2025
40883583 (PubMed )
Supplement: 42003_2025_8738_MOESM4_ESM.xlsx › Supplementary_Data_3
Disruption of the cerebrospinal fluid-plasma protein balance in cognitive impairment and aging.
Farinas A et al.
Nature Medicine, 2025
40665050 (PubMed )
Supplement: 41591_2025_3831_MOESM3_ESM.xlsx › ST2
A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease.
Oh HS et al.
Nature Medicine, 2025
40164724 (PubMed )
Supplement: 41591_2025_3565_MOESM3_ESM.xlsx › ST2
IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome.
Araya P et al.
Cell Reports, 2022
36577365 (PubMed )
Supplement: NIHMS1861170-supplement-3.xlsx › D._TAU_vs._SOMAscan_T21
Multiomics study of nonalcoholic fatty liver disease.
Sveinbjornsson G et al.
Nature Genetics, 2022
36280732 (PubMed )
Supplement: 41588_2022_1199_MOESM4_ESM.xlsx › Supplementary_Table_11_-_Soma
Genome- and epigenome-wide studies of plasma protein biomarkers for Alzheimer's disease implicate TBCA and TREM2 in disease risk.
Hillary RF et al.
Alzheimer's & Dementia (amsterdam, Netherlands), 2022
35475137 (PubMed )
Supplement: DAD2-14-e12280-s002.xlsx › Table_S6_-_SOMAmer_details
Select a paper to view details